New drugs developed by Korean pharmaceutical companies are showing strength in the prescription market. Hanmi Pharmaceutical’s Rosuzet and HK Inno. N’s K-CAB has recorded over ₩10 billion in monthly sales and made a good start.

According to the market research institution UBIST on the 19th, the hyperlipidemia treatment Lipitor recorded No.1 in Q1 making ₩48.8 billion in outpatient prescriptions in Q1 this year. This is a 1.8% decrease from the same period of the previous year, but still a solid lead over the runner-up.

Lipitor is Pfizer Korea’s dyslipidemia treatment that contains atorvastatin that was introduced to the Korean market in 1999. Despite the fierce competition w